Zacks Investment Research downgraded shares of PERNIX THERAPTC (PTX) from NEUTRAL to UNDERPERFORM on March 27, 2013, with a target price of $4.90.
Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company's product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is b
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PERNIX THERAPTC (PTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment